Gilead Sciences, Inc. (GILD) operating KPIs
GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 11/30105% above fair value
$170.68+5.07 (+3.06%)
Close on Oct 30, 2026Market cap $211.64BP/E –Yield 1.85%
Gilead Sciences gross-to-net deductions as % of gross product sales (%) (%)
Form 10-K MD&A Gross-to-Net Deductions
Latest, FY2025
41.0%
Period ended Dec 31, 2025
Change on a year earlier
+3.0 pts
38.0% in FY2024
History
8 years
Since FY2016
Sources
4
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Gross-to-net deductions as % of gross product sales (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 41.0% | +3.0 pts | Form 10-K (gild-20251231.htm, filed 2026-02-24) ↗ |
| FY2024 | Dec 31, 2024 | 38.0% | 0.0 pts | Form 10-K (gild-20251231.htm, filed 2026-02-24) ↗ |
| FY2023 | Dec 31, 2023 | 38.0% | +3.0 pts | Form 10-K (gild-20231231.htm, filed 2024-02-23) ↗ |
| FY2022 | Dec 31, 2022 | 35.0% | 0.0 pts | Form 10-K (gild-20231231.htm, filed 2024-02-23) ↗ |
| FY2021 | Dec 31, 2021 | 35.0% | – | Form 10-K (gild-20221231.htm, filed 2023-02-22) ↗ |
| FY2018 | Dec 31, 2018 | 43.0% | +3.0 pts | Form 10-K (a2018form10-k.htm, filed 2019-02-26) ↗ |
| FY2017 | Dec 31, 2017 | 40.0% | 0.0 pts | Form 10-K (a2018form10-k.htm, filed 2019-02-26) ↗ |
| FY2016 | Dec 31, 2016 | 40.0% | – | Form 10-K (a2018form10-k.htm, filed 2019-02-26) ↗ |
Cite this data
StockData. (2026). Gilead Sciences Gross-to-net deductions as % of gross product sales (%) (%), annual FY2016–FY2025 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/gtn_pct_gross_sales
See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.